-
July 30, 2021 Lupin Acquires Southern Cross Pharma in Australia
-
July 13, 2021 Lupin Launches Tavaborole Topical Solution in the United States
-
July 1, 2021 Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) for the Treatment of Trichomoniasis
-
June 30, 2021 Lupin Receives Tentative U.S. FDA Approval for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) Tablets under PEPFAR
-
June 25, 2021 Lupin Launches Emtricitabine and Tenofovir Disoproxil Fumarate Tablets in the United States
-
June 17, 2021 Lupin Receives U.S. FDA Approval for Sevelamer Hydrochloride Tablets
-
June 14, 2021 Lupin receives UK marketing authorization for Luforbec® 100/6 µg pMDI, first branded generic alternative to Fostair® 100/6 µg pMDI for treatment of Asthma & COPD
-
June 11, 2021 Lupin donates Oxygen generation plants in Maharashtra, Madhya Pradesh & Gujarat to aid COVID-19 relief efforts
-
June 3, 2021 Lupin Launches Authorized Generic Version of Brovana® in the United States
In this section
Media Contacts
-
Shweta Munjal
Head – Corporate Communications
shwetamunjal@lupin.com